Improving outcomes after pediatric stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests different ways to improve recovery and reduce complications after a stem cell transplant from a donor. It's designed for children who are about to receive this type of transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 week and 18 years old.
- Your child must be planning to receive a donor stem cell transplant within the next 4 months.
- Your child's situation must not be considered terminal with no hope for active treatment.
- A suitable donor must be found for the transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying better ways to manage stem cell transplants for children and young adults with acute lymphoblastic leukemia (ALL). It aims to improve outcomes by testing different approaches to transplant care.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
This trial offers a special type of stem cell transplant for children and young adults. It uses a machine to remove certain immune cells (alpha/beta T cells and CD19+ cells) from the donated stem cells, which may lower the risk of graft-versus-host disease. The study includes patients who need a first transplant, a second transplant, or a stem cell boost.
Hear when a new Haematopoietic Stem Cell Transplant, Allogeneic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.